Post-ADA 2026 Synthesis: Aleniglipron Phase 2b Published in Nature Medicine, Wegovy Pill Surpasses 3 Million Prescriptions, CVS Caremark Resets GLP-1 Formulary, and PCAC July 23–24 Review of BPC-157, TB-500, and Five Research Peptides Approaches — June 9, 2026
Table of Contents
- Post-ADA 2026: Four Concurrent Stories That Define the Next Phase
- Aleniglipron Phase 2b Published in Nature Medicine: The First Oral Non-Peptide GLP-1 RA With Full Peer-Reviewed Data
- Wegovy Pill Crosses 3 Million Prescriptions: What the Adoption Curve Means
- CVS Caremark Formulary Reset: Foundayo and Zepbound Gain Parity With Wegovy
- FDA PCAC July 23–24, 2026: The Most Consequential Research Peptide Regulatory Vote in Years
- Pipeline Lookhead: What Comes Next After ADA 2026
Post-ADA 2026: Four Concurrent Stories That Define the Next Phase
The American Diabetes Association's 86th Scientific Sessions closed on June 8, 2026, but the week's consequence didn't end with the final poster session. Four parallel developments — a major journal publication, a commercial milestone, a formulary shakeup, and a regulatory countdown — are now defining what comes next in both the approved GLP-1 market and the research peptide space. This post synthesizes those four threads as they stood on June 9, 2026, the first full day after ADA 2026 closed.
Aleniglipron Phase 2b Published in Nature Medicine: The First Oral Non-Peptide GLP-1 RA With Full Peer-Reviewed Data
The most scientifically significant post-conference development was the simultaneous publication and oral presentation of the aleniglipron (GSBR-1290) ACCESS Phase 2b trial in Nature Medicine on June 5, 2026. Lead author Julio Rosenstock, MD — Chair of the aleniglipron Steering Committee and Clinical Professor at UT Southwestern — delivered the oral talk at ADA 2026, making aleniglipron the first oral non-peptide GLP-1 RA to have its pivotal Phase 2b results published in a flagship peer-reviewed journal concurrent with a conference presentation. The Nature Medicine paper (Rosenstock et al., 2026) confirms the dose-ranging ACCESS results: dose-dependent, statistically significant, placebo-adjusted weight loss with no plateau observed at 36 weeks, and continued loss up to 16.2% in the open-label extension period. The overall discontinuation rate across the trial was 10.4% — notably lower than rates observed in early injectable GLP-1 trials and competitive with orforglipron's Phase 3 discontinuation data. Importantly, tolerability improved as patients progressed through the dosing period: from weeks 28–44, AE-related discontinuations fell to 3.7% at doses ≥120 mg. The ACCESS II 44-week extended data — showing 16.3% placebo-adjusted weight loss at 180 mg — remain the highest published figure for any oral GLP-1 receptor agonist, exceeding oral semaglutide 25 mg (13.6% in OASIS 4) and orforglipron's Phase 3 results. Phase 3 initiation remains on track for Q3 2026 following positive FDA end-of-Phase 2 feedback. The Nature Medicine publication meaningfully elevates aleniglipron's scientific profile: peer-reviewed full data in a top-5 medical journal is a standard that injectable GLP-1 programs met years ago but that oral small-molecule programs are only now reaching.
Wegovy Pill Crosses 3 Million Prescriptions: What the Adoption Curve Means
On June 7, 2026 — during ADA — Novo Nordisk announced that oral semaglutide 25 mg (Wegovy tablet) has surpassed 3 million prescriptions since its January 2026 launch, with approximately one prescription filled every five seconds at peak. This milestone arrived roughly five months post-launch, making oral Wegovy's adoption curve among the fastest for any branded obesity therapy in U.S. history. The 3 million figure has two distinct implications. First, it validates the oral GLP-1 market hypothesis: there is a large, clinically meaningful segment of patients with obesity who prefer or require a pill over an injection — whether due to needle aversion, logistics, or cost. Second, it substantially raises the competitive bar for aleniglipron, ASC30, and other oral GLP-1 candidates targeting the same population. Any oral GLP-1 entering this market must now differentiate on tolerability, efficacy, dosing convenience, or cost against an established product with a proven prescriber base. For context: Wegovy injectable surpassed 1 million prescriptions in approximately 6 months post-launch in 2021. The oral version reached 3× that in the same timeframe — a direct result of broader insurance coverage and telehealth infrastructure that did not exist in 2021.
CVS Caremark Formulary Reset: Foundayo and Zepbound Gain Parity With Wegovy
A parallel commercial development with significant market implications: CVS Caremark announced in early June 2026 that it is resetting its GLP-1 obesity formulary to place Eli Lilly's Foundayo (orforglipron) and Zepbound (tirzepatide) on equal preferred formulary status with Novo Nordisk's Wegovy-class products. Foundayo was added to formulary on June 1, 2026; Zepbound returns as a preferred option starting October 1, 2026. This is a meaningful reversal of the prior period's dynamic, in which CVS Caremark had given commercial preference to Wegovy-class drugs in exchange for rebate agreements. The dual addition signals that CVS is pursuing a competitive-bidding model for this category rather than exclusive preferred placement — a pattern that generally benefits patients through lower out-of-pocket costs and broader access, while compressing manufacturer margins. For Eli Lilly, the CVS shift is a significant commercial win: Foundayo now has both the FDA approval (April 2026) and preferred formulary access at one of the largest pharmacy benefit managers in the U.S. simultaneously, an unusually fast commercial ramp for a new obesity drug.
FDA PCAC July 23–24, 2026: The Most Consequential Research Peptide Regulatory Vote in Years
For researchers and clinicians tracking the compounding peptide landscape, the most consequential near-term event is the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, at the FDA White Oak Campus. The committee will vote on seven peptides for potential inclusion on the 503A Bulks List — a vote that, if favorable, would allow licensed compounding pharmacies to legally prepare these substances with a prescription for the first time since the 2023 restrictions took effect. The seven peptides under formal review: - July 23 (Day 1): BPC-157, KPV, TB-500, MOTS-c - July 24 (Day 2): Emideltide (DSIP), Semax, Epitalon All seven were moved from Category 2 (significant safety concerns, banned from compounding) back to Category 1 (eligible for review) per the February 27, 2026 HHS announcement. The formal FDA docket (FDA-2025-N-6895) has been open for public comment through July 9, 2026 — the last date for written comments to be formally presented to the committee. The docket itself remains open until July 22. A critical clarification: the July PCAC vote is not FDA drug approval. A favorable committee recommendation would move each substance toward formal rulemaking to add it to the 503A Bulks List — a separate administrative process that typically takes additional months. Compounding pharmacies cannot legally prepare 503A-listed substances simply because the committee voted favorably; rulemaking must be completed. However, a positive PCAC recommendation is the first required step on that pathway, and the meeting represents the most substantive formal federal review of these research peptides' compounding eligibility in at least three years. For BPC-157, TB-500, and MOTS-c specifically — the three most widely used research peptides in the compounding gray market — the July vote will be closely watched by the research, sports medicine, and regenerative medicine communities.
Pipeline Lookhead: What Comes Next After ADA 2026
ADA 2026 was the densest single obesity data conference in history by most metrics — five distinct receptor targets, pivotal Phase 3 data from at least three programs (TRIUMPH-1, TRIUMPH-4, SYNCHRONIZE-1, ZUPREME-1), and Phase 2 data from half a dozen more. What comes next: Q3 2026 expected events include: aleniglipron Phase 3 initiation; petrelintide Phase 3 initiation (Zealand Pharma / Roche); MBX-4291 12-week Phase 1 MAD Part C data; and the PCAC July 23–24 vote on research peptide compounding eligibility. Retatrutide's NDA filing is planned for Q4 2026, with FDA decision expected mid-to-late 2027. The next major conference catalyst is likely the European Association for the Study of Obesity (EASO) annual meeting and the EASD Scientific Sessions, both expected in the second half of 2026. The field enters post-ADA with more Phase 3 programs simultaneously active across more distinct mechanisms than at any prior point in obesity pharmacology history.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
Related Articles
The ADA 2026 Scientific Sessions open today in New Orleans (June 5–8) with an unprecedented density of late-stage obesity and diabetes pipeline data: Eli Lilly presents full TRIUMPH-1 retatrutide data (28.3% weight loss, 80 wks), Boehringer Ingelheim presents complete SYNCHRONIZE-1 survodutide results (16.6% vs 3.2% placebo, 76 wks), Novo Nordisk hosts a REIMAGINE 1–3 symposium for CagriSema in T2D, and presents zenagamtide Phase 2 data (up to 24.3% weight loss) as its next-generation GLP-1/amylin molecule.
ADA 2026 Day 3: Retatrutide TRIUMPH-4 shows 28.7% weight loss plus 75.8% WOMAC knee pain reduction — highest pain relief in any obesity-OA drug trial. Zenagamtide (amycretin) posts 14.6% weight loss and 89% A1C target achievement in Phase 2 T2D, triggering Phase 3 T2D program for H2 2026. CagriSema functional brain imaging reveals the amylin+GLP-1 appetite-circuit mechanism behind its 22.7% weight loss.
ADA 2026 closes with three major findings: Pfizer's berobenatide delivers 12.3% placebo-adjusted weight loss with once-monthly injection — potentially the first monthly GLP-1 RA to reach Phase 3. Orforglipron (Foundayo) shows up to 30.4 lbs weight loss across all menopause stages in ATTAIN sub-analyses, and ACHIEVE-2/-5 confirm T2D superiority. Ascletis's ASC30 oral GLP-1 posts 7.7% placebo-adjusted weight loss at 13 weeks with 2–3x greater in vitro potency than orforglipron.